Table 2. MRI findings of ULCD, ESS, and LMS.

MRI findings		ULCD (n=30)	MPMUT (n=33)		p-value
			ESS (n=18)	LMS (n=15)
Maximum size (cm)		12.3±6.0	9.8±4.8	9.8±4.3	0.177*
Location
	Endometrium (submucosal)	3 (10.0)	16 (88.9)	5 (33.3)	<0.001†
	Myometrium (intramural)	11 (36.4)	2 (11.1)	7 (46.7)	<0.001‡
	Subserosal	16 (53.3)	0 (0.0)	3 (20.0)	0.051§
Tumor margin					<0.001†
	Well-defined	29 (96.7)	6 (33.3)	5 (33.3)	<0.001‡
	Ill-defined	1 (3.3)	12 (66.7)	10 (66.7)	<0.001§
Peripheral band of low T2 SI					<0.001†
	Present	3 (10.0)	15 (83.3)	4 (26.7)	<0.001‡
	Absent	27 (90.0)	3 (16.7)	11 (73.3)	0.308§
Peripheral crescent lesion					0.479†
	Present	5 (16.7)	8 (44.4)	1 (6.7)	0.078‡
	Absent	25 (83.3)	10 (55.6)	14 (93.3)	0.069§
Speckled appearance					<0.001†
	Present	27 (90.0)	6 (33.3)	9 (60.0)	<0.001‡
	Absent	3 (10.0)	12 (66.7)	6 (40.0)	0.048§
Hemorrhage					0.215†
	Present	9 (30.0)	3 (16.7)	13 (86.7)	0.491‡
	Absent	21 (70.0)	15 (83.3)	2 (13.3)	0.001§
Local invasion					0.079†
	Present	0 (0.0)	3 (16.7)	2 (13.3)	0.090‡
	Absent	30 (100.0)	15 (83.3)	13 (86.7)	0.201§
Pelvic lymphadenopathy					0.515†
	Present	0 (0.0)	0 (0.0)	2 (13.3)	0.112‡
	Absent	30 (100.0)	18 (100.0)	13 (86.7)	0.201§
Distant metastasis					0.282†
	Present	0 (0.0)	0 (0.0)	3 (20.0)	0.112‡
	Absent	30 (100.0)	18 (100.0)	12 (80.0)	0.057§

Except where indicated, data are numbers of patients or mean±standard deviation and numbers in parenthesis are percentages.

ESS, endometrial stromal sarcoma; LMS, leiomyosarcoma; MPMUT, malignant pure mesenchymal uterine tumor; SI, signal intensity; ULCD, uterine leiomyoma with cystic degeneration.

^*One-way analysis of variance; ^†χ² test, ULCD vs. MPMUT; ^‡χ² test, ULCD vs. ESS; ^§χ² test, ULCD vs. LMS.